What is the price target for TTRX stock?
8 analysts have analysed TTRX and the average price target is 7.22 USD. This implies a price increase of 113.51% is expected in the next year compared to the current price of 3.38.
TURN THERAPEUTICS INC (TTRX) Forecast, Price Target & Analyst Ratings
NASDAQ:TTRX • US90021W1053
Current stock price
3.38 USD
+0.06 (+1.96%)
Last:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for TURN THERAPEUTICS INC (TTRX).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$0.04
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.22
Upside
+ 113.51%
From current price of $3.38 to mean target of $7.22, Based on 8 analyst forecasts
Low
$6.21
Median
$7.22
High
$8.40
Price Target Revisions
1 Month
0.00%
3 Months
N/A
Price Target Summary
8 Wall Street analysts provided a forecast for the next 12 months for TTRX. The average price target is 7.22 USD. This implies a price increase of 113.51% is expected in the next year compared to the current price of 3.38.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.50%
TTRX was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about TTRX.
In the previous month the buy percentage consensus was at a similar level.
TTRX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-24 | D. Boral Capital | Maintains | Buy -> Buy |
| 2026-01-20 | D. Boral Capital | Maintains | Buy -> Buy |
| 2025-12-29 | D. Boral Capital | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2025
- EPS Estimate
- -$0.04
- Revenue Estimate
- N/A
- Revenue Q2Q
- N/A
- EPS Q2Q
- N/A
- Number of Analysts
- 3
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates 2025 - 2028
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A -98.73% | N/A -100.00% | ||||
| EBITDA YoY % growth | -4.157M | -2.254M 45.78% | -1.75M 22.38% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.21M | -2.308M 45.17% | -1.797M 22.14% | N/A -114.15% | N/A -1.99% | N/A -81.91% | N/A | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A 24.14% | N/A -131.82% | N/A 33.33% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.04 | -0.03 | -0.03 | -0.03 | -0.03 25.00% | -0.05 -100.00% | -0.11 -340.00% | -0.08 -166.67% | -0.12 -300.00% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | N/A | -905.76K | -938.4K 31.33% | -981.24K 48.72% | -1.099M | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-60.34%
EPS Next 5 Year
-28.75%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
TURN THERAPEUTICS INC / TTRX Forecast FAQ
How many analysts cover TURN THERAPEUTICS INC (TTRX) stock?
The number of analysts covering TURN THERAPEUTICS INC (TTRX) is 8.